Alnuctamab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A bispecific T-cell engager (BiTE) antibody directed against both the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, alnuctamab binds bivalently to BCMA expressed on tumor cells and monovalently to CD3 expressed on cytotoxic T-lymphocytes (CTLs). This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.

**Synonyms:** - ALNUC - ALNUCTAMAB - Anti-BCMA/CD3 Bispecific Antibody CC-93269 - BCMA x CD3 T Cell Engaging Antibody CC-93269 - BCMA x CD3 T-cell Engaging Antibody CC-93269 - BCMA/CD3 T-cell Bi-specific Antibody CC-93269 - BCMA/CD3-directed Bispecific T-cell Engager Antibody CC-93269 - BCMAxCD3 BiTE Antibody CC-93269 - BCMAxCD3 TCB CC-93269 - BMS 986349 - BMS-986349 - BMS986349 - Bi-specific Antibody CC-93269 - CC 93269 - CC-93269 - CC93269 - EM901